• Applications & Products
  • Media Formulation
  • About InVitria
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
      • Food Science
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Insulin-Transferrin Supplements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Lysozyme
    • Products
      • Cellastim S – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin – Recombinant human albumin
      • Optiferrin – Recombinant human transferrin
      • Lacromin – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac – Recombinant human lysozyme
      • Leukemia Inhibitory Factor
      • OptiPEAK® HEK293t
      • OptiPEAK® T Lymphocyte XPR
      • OptiVERO®
      • OptiFRZ®
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Applications
  • Products
  • Contact Us
  • Home
  • Knowledge Base

Knowledge Base

or click to browse

Recent Additions

  • OptiFRZ Guidelines for Use
  • VERO Expansion in the iCellis® Bioreactor with Chemically Defined and Blood Free Virus Production Media
  • High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation
  • Chemically Defined Upstream and Downstream Lentivirus Production for High T Cell Transduction
  • Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin
  • DMSO-Free Cryopreservation Formulation As An Alternative Cryopreservation Method For Cell-based Therapies
  • DMSO-Free Cryopreservation of Mesenchymal Stem Cells in Chemically Defined Systems
  • DMSO-Free Cryopreservation of Human T Lymphocytes in Chemically Defined Systems
  • Formulation and production of a blood-free and chemically defined virus production media for VERO cells
  • Evaluation of Transfection Reagents for High Titer Viral Vector Production in the iCELLis Nano Bioreactor
  • Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media
  • Exbumin – Reconstitution Application Note
  • OptiPEAK T Lymphocyte XPR Expansion of T Cells without Serum in Chemically Defined Media
  • InVitria Expands European and UK Footprint
  • Use of Gas Permeable Rapid Expansion (G-Rex®) Culture ware with Chemically Defined Media for Simplistic and Robust T Lymphocyte Expansion
  • Chemically Defined iCELLis® Bioreactor-Based Viral Vector Manufacturing – Application of Aber Biomass Probes to Inform Transfection Timing
  • AAV Production – How To Improve Transfection Efficiency and Titer Yield
  • Blood-Free Fetal Bovine Serum Alternatives in Cell Culture Media
  • Improvement of Vaccine Manufacturing Process with Use of Recombinant HSA Excipient
  • Revolutionizing Cell Immunotherapies with Serum Free T Cell Media
  • Lentrivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield
  • Chemically Defined iCELLis® Bioreactor-Based Lentiviral Vector Mass Production
  • Improving Vaccine Development, Performance, and Stability with Recombinant HSA Excipient
  • Improvements in Viral Vector Manufacturing Process with Chemical Definition of Cell Culture Media & Excipients
  • Emergence of Blood-Free Recombinant Human Albumin
  • Product Catalog
  • Formulation and production of a blood‐free and chemically defined virus production media for VERO cells
  • Accelerating Vaccine Development Through Use of Blood-Free Components
  • OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note
  • OptiVERO – Guidelines for Use
  • rHSA Reconstitution Video Protocol
  • 2020 Product Catalog
  • OptiPEAK HEK293t – Product Specifications
  • OptiPEAK HEK293t – Safety Data Sheet
  • Optibumin – Safety Data Sheet
  • Lysosure – Safety Data Sheet
  • Lysobac – Safety Data Sheet
  • Lysobac – Brochure – E.Coli Lysis
  • Lysobac – Guidelines for Use
  • ITSE+A – Guidelines for Use
  • ITSE AF – Safety Data Sheet
  • ITSE AF – Guidelines for Use
  • ITSE AF – Brochure
  • ITS – Guidelines for Use
  • ITS – Specifications
  • Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note
  • Exbumin – Safety Data Sheet
  • Exbumin – Guidelines for Use
  • Optiferrin – Product Brochure
  • Optiferrin – Guidelines for Use
  • Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes
  • Cellastim S – Safety Data Sheet
  • Cellastim S – Reconstitution Application Note
  • Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin
  • Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease
  • Solving the Vaccine Supply Challenge
  • Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times
  • SARS-CoV2 and Influenza – Double Threat
  • High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media
  • Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease
  • Transient Transfection Protocol – Enhancement of Transfection Efficiency Using Recombinant Transferrin with Serum-Free HEK293 Media
  • Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media
  • Controlling Impurities in Cell Culture Media
  • Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells
  • BioInnovation on Parade: Philly Stands Proud for BIO 2019!
  • Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells Application Note
  • Explore the Latest Developments in T-reg Research and Clinical Application
  • Exploring the Latest Research and Opportunities in T-reg Therapy
  • OptiVERO – Formulation of a blood-free and chemically defined virus production media for VERO cells
  • Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
  • ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy
  • Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines
  • OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media
  • Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture
  • Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial
  • ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy
  • Phacilitate 2019 and World Stem Cell Summit
  • Join InVitria at ECI 2019
  • Join InVitria at Phacilitate 2019
  • Cellastim S – Guidelines for Use
  • Happy Holidays from the InVitria Team!
  • BIO Europe 2018: From Lab Innovations to Commercial Realities
  • The Emergence of Serum-Free Cell Culture Media – Blood-Free Chemically Defined Components
  • InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area
  • BIO 2018: The Emergence of Gene & Cell Therapy
  • InVitria at the American Association of Immunologists 2018 Conference
  • Optiferrin – Recombinant Transferrin an Iron Transport Protein in Cell Culture Media
  • InVitria’s Top Insights from ISCT 2018 – Montreal
  • 3 Takeaways from the World Vaccine Congress 2018
  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2023 InVitria

    • Terms
    • Privacy
    • Sitemap